TRANSCATHETER AORTIC VALVE REPLACEMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Transcatheter Aortic Valve Replacement Market, By Procedure Type (Transfemoral, Transapical, and Other Approaches), By Device Type (Balloon-Expandable Valves and Self-Expanding Valves), By End User (Hospitals, Ambulatory Surgical Centers, Independent Cardiac Catheterization Labs, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On March 2024, Medtronic plc, a medical device company, announced that the U.S. Food and Drug Administration (FDA) approved the Evolut FX+ transcatheter aortic valve replacement system for treating symptomatic severe aortic stenosis. The new Evolut FX+ TAVR system retains the valve performance benefits of the previous Evolut TAVR platform and is designed to enhance coronary access.
In June 2023, egnite, Inc., a digital health company specializing in cardiovascular care, and JenaValve Technology, Inc., a developer and manufacturer of innovative TAVR systems, announced a strategic partnership. This collaboration aims to enhance the understanding of the care paradigm and associated outcomes for patients with aortic regurgitation (AR).
On January 2024, Eisenhower Health became the first hospital in the U.S. to be designated as an Edwards Benchmark Program Case Observation Site for treating aortic stenosis in patients undergoing transcatheter aortic valve replacement